Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01), Zacks reports.
Barinthus Biotherapeutics Stock Performance
Shares of BRNS stock traded down $0.03 on Friday, hitting $1.35. The company’s stock had a trading volume of 1,840 shares, compared to its average volume of 21,198. Barinthus Biotherapeutics has a fifty-two week low of $1.21 and a fifty-two week high of $5.10. The stock’s 50 day moving average is $1.53 and its 200-day moving average is $2.21. The company has a market capitalization of $52.69 million, a PE ratio of -0.73 and a beta of -0.52.
Wall Street Analyst Weigh In
A number of research analysts recently commented on the stock. Barclays decreased their price target on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating on the stock in a research note on Thursday, June 13th. William Blair reaffirmed an “outperform” rating on shares of Barinthus Biotherapeutics in a research report on Thursday, June 13th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Barinthus Biotherapeutics in a report on Friday, June 7th.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Further Reading
- Five stocks we like better than Barinthus Biotherapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Stock Sentiment Analysis: How it Works
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- How to Invest in the Best Canadian Stocks
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
